NASDAQ$TWST
Twist Bioscience Corporation · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Twist Bioscience achieved record revenue and exceeded projections in Q1 2024.
Twist Bioscience reported a strong start to fiscal year 2024, achieving record revenue of $71.5 million, a 32% increase compared to the same period last year. The company's gross margin was 40.5%.
- Total revenue reached a record $71.5 million, up 32% year-over-year.
- Orders increased to $77.5 million, a 19% increase year-over-year.
- SynBio revenue increased to $26.8 million, compared to $21.7 million for the same period last year.
- NGS revenue increased to $39.4 million, compared to $24.4 million for the same period last year.
Headline financials
Revenue & EPS history
Twist Bioscience · Revenue · Quarterly
$71.5M
Revenue by segment
Twist Bioscience · $218M total across 2 segments · Q3 2023
- NGS Applications$120M+23.7%55.0%
- DNA Synthesis & Protein$98M+22.5%45.0%
Forward guidance
Twist Bioscience updated its fiscal year 2024 financial guidance, projecting total revenue between $288 million and $293 million and gross margin between 40% and 41%.
Tailwinds
- Total revenue is expected to be in the range of $288 million to $293 million, growth of 18 to 20 percent
- SynBio revenue is expected to be in the range of $114 million to $117 million, indicating year over year growth of 16 to 19 percent
- NGS revenue is expected to be in the range of $150 million to $152 million, indicating year over year growth of 21 to 23 percent
- Biopharma revenue is expected to be approximately $24 million, indicating year over year growth of approximately 3 percent
- Gross margin is expected to be approximately 40% to 41% for fiscal 2024, an increase across the range
Headwinds
- Loss from operations before taxes of approximately $189 million to $194 million, an increase from $180 million to $188 million provided previously
- Total revenue of approximately $70 million to $71 million for the second quarter of fiscal year 2024
- SynBio revenue of approximately $28.5 million for the second quarter of fiscal year 2024
- NGS revenue of approximately $37 million to $38 million for the second quarter of fiscal year 2024
- Biopharma revenue of approximately $4.5 million for the second quarter of fiscal year 2024
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+0.1%
Avg return
Earnings day
-2.1%
Avg return
5 days after
+0.8%
Avg return
30 days after
47%
14 / 30 earnings
Positive
+29.7%
Q4 2023
Best reaction
-23.2%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -7.3% | -5.9% | +19.6% | |
| Q1 2026 | +13.8% | -5.9% | -10.2% | |
| Q4 2025 | -10.0% | -14.9% | +3.4% | |
| Q2 2025 | -8.5% | -16.9% | -20.8% | |
| Q1 2025 | +0.7% | -0.1% | -19.7% | |
| Q4 2024 | +12.0% | +14.5% | +20.9% | |
| Q3 2024 | -14.6% | -16.0% | -18.5% | |
| Q2 2024 | +28.9% | +34.9% | +31.1% | |
| Q1 2024 | +9.5% | +5.1% | +16.9% | |
| Q4 2023 | +29.7% | +24.9% | +81.5% | |
| Q3 2023 | +14.9% | +9.3% | +14.0% | |
| Q2 2023 | +3.6% | +2.1% | +26.0% | |
| Q1 2023 | -23.2% | -15.2% | -37.1% | |
| Q4 2022 | +0.8% | +0.5% | -0.6% | |
| Q3 2022 | +20.8% | +12.4% | -17.2% | |
| Q2 2022 | -9.9% | -16.3% | -12.6% | |
| Q1 2022 | -1.0% | +6.0% | -21.0% | |
| Q4 2021 | -12.6% | -14.1% | -22.4% | |
| Q3 2021 | -9.1% | -15.8% | -7.6% | |
| Q2 2021 | +6.2% | -9.4% | -12.4% | |
| Q1 2021 | -16.8% | -5.5% | -38.1% | |
| Q4 2020 | -9.9% | -0.8% | +44.3% | |
| Q3 2020 | -7.2% | -16.3% | -4.8% | |
| Q2 2020 | +5.1% | +4.6% | +0.7% | |
| Q1 2020 | +21.3% | +14.0% | +31.4% | |
| Q4 2019 | +4.6% | +5.8% | -15.5% | |
| Q3 2019 | -11.2% | -11.8% | -13.9% | |
| Q2 2019 | -9.9% | -9.7% | -3.9% | |
| Q1 2019 | -9.2% | -11.8% | -6.9% | |
| Q4 2018 | -9.2% | -9.4% | +18.6% | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro